ClinicalTrials.gg
Sign In
CompletedNCT05979233Updated Oct 15, 2026

One Session Vs Staged Management of Calcular Obstructive Jaundice

An interventional study of staged managment and one session ERCP then LC in Calcular Obstructive Jaundice and Gall Bladder Disease, sponsored by Minia University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Minia University · Not applicable, Interventional, and Treatment

Updated Oct 15, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

to compare the outcomes between doing ERCP and laparoscopic cholecystectomy in one session Vs staged management

Read the detailed description

to compare the outcomes between 3 groups: in the 1st group we will do ERCP then laparoscopic cholecystectomy in the same session, in the 2nd group we will do laparoscopic cholecystectomy then ERCP in the same session in group 3 we will do staged management

02

Conditions studied

  • Calcular Obstructive Jaundice
  • Gall Bladder Disease

Browse trials for

03

In context

Gallbladder Diseases

92 studies on the registry are indexed under Gallbladder Diseases; 19 are open to participants now.

This study's enrollment of 110 is above the median of 72 across 59 interventional studies indexed under Gallbladder Diseases.

Browse Gallbladder Diseases studies →

Lead sponsor

Minia University is the lead sponsor of 370 studies on the registry; 117 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Minia University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age from 18-70 year
  • combined CBD and gall stone
  • stone less than 1.5 cm
  • fit for surgery
  • no upper abdominal surgery

Exclusion criteria

Exclusion Criteria:

  • age \<18 and >70
  • unfit for surgery
  • stone more than 1.5 cm
  • upper abdominal surgery
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Active comparator
    staged managment

    ERCP then interval laparoscopic cholecystectomy

    Procedure: staged managment

  • Experimental
    one session ERCP then LC

    one session ERCP then LC

    Procedure: one session ERCP then LC

  • Experimental
    one session LC then ERCP

    one session LC then ERCP

    Procedure: one session LC then ERCP

Interventions

  • Procedurestaged managment

    staged management

  • Procedureone session ERCP then LC

    one session ERCP then LC

  • Procedureone session LC then ERCP

    one session LC then ERCP

06

What researchers measure

Primary outcomes

  1. total cost

    total cost in Egyptian pound

    Time frame: 6 months

  2. hospital stay

    total hospital stay in days

    Time frame: 6 months

Secondary outcomes

  1. complications

    early postoperative complications

    Time frame: 30 days

07

Study locations

1 site
  • Faculty of medicine
    Minya, 61511, Egypt
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Apr 2024, 8 months.

Of 32 non-industry interventional studies with no phase under Gallbladder Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 26. This study's 8 months is below that.

Counting every sponsor, half of 34 studies reached it within 14 months; a quarter within 8 and three quarters within 26.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Feb 2024 → Apr 2024 and completion Feb 2024 → Feb 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2023
First posted
Aug 7, 2023
StartActual
Aug 5, 2023
Primary completionActual
Apr 21, 2024was Feb 2024
CompletionActual
Feb 20, 2025was Feb 2024
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 15, 2026
Primary completion
Feb 15, 2024→Apr 21, 2024 (actual)
Oct 15, 2026
Study completion
Feb 20, 2024→Feb 20, 2025 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Recruiting→Completed
    Primary completion Feb 15, 2024→Apr 21, 2024 (now actual)
    Study completion Feb 20, 2024→Feb 20, 2025 (now actual)
    + 4 other changes: index terms, verification date, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05979233
Lead sponsor
Minia University
Responsible party
Alaa Mstafa Hassan Sewefy (MD, professor & consultant of general surgery, Department of surgery, Minia university hospital, Egypt, Minia University) — Principal investigator
First posted
Aug 7, 2023
Start date
Aug 5, 2023
Primary completion
Apr 21, 2024
Completion
Feb 20, 2025
Last update
Oct 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Gallbladder Diseases →

Other studies from this sponsor

Minia University →

Start the discussion